49. 全身性エリテマトーデス
[臨床試験数:827,薬物数:638(DrugBank:168),標的遺伝子数:108,標的パスウェイ数:191

Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04184258
(ClinicalTrials.gov)
July 1, 20191/12/2019Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem CellsTreatment of Systemic Lupus Erythematosus With Pooled Allogenic Olfactory Mucosa Derived Mesenchymal Stem CellsSystemic Lupus ErythematosusBiological: Pooled mesenchymal stem cell;Other: Standard treatment according to the Clinical protocolsInstitute of Biophysics and Cell Engineering of National Academy of Sciences of BelarusBelarusian State Medical UniversityRecruiting18 Years75 YearsAll10Phase 1/Phase 2Belarus
2NCT02633163
(ClinicalTrials.gov)
October 26, 201815/12/2015Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory LupusSystemic Lupus ErythematosusDrug: Low Dose Mesenchymal Stem Cells (MSCs);Drug: High Dose Mesenchymal Stem Cells (MSCs);Drug: Placebo InfusionMedical University of South CarolinaNULLRecruiting18 Years65 YearsAll81Phase 2United States
3NCT03562065
(ClinicalTrials.gov)
July 1, 201822/5/2018Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical CordTreatment of Refractory Systemic Lupus Erythematosus by Injection of Allogeneic Mesenchymal Stem Cells Derived From the Umbilical CordLupus Erythematosus;Stem Cell TransplantBiological: mesenchymal stem cellsAssistance Publique - Hôpitaux de ParisNULLNot yet recruiting18 Years70 YearsAll10Phase 1/Phase 2France
4EUCTR2017-001400-29-FR
(EUCTR)
16/03/201831/07/2018Treatment of systemic lupus erythematosus by injection iv of mesenchymal stem cells (MSC-LES)Treatment of severe refractory systemic lupus erythematosus by injection of allogeneic mesenchymal stem cells derived from the umbilical cord - MSC SLE - MSC-LES Treatment of Systemic Lupus Erythematosus refractory to standard treatments.
MedDRA version: 20.0;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: ALLOGENEIC MESENCHYMAL STROMAL CELLS DERIVED FROM THE UMBILICAL CORD
Product Code: 0
INN or Proposed INN: 0
Other descriptive name: CSM allogéniques issues de cordons ombilicaux ( MTI-PP)
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
10Phase 1;Phase 2France
5NCT03219801
(ClinicalTrials.gov)
August 1, 201710/7/2017Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Systemic Lupus ErythematosusEvaluation of Safety and Efficacy in Patients With Systemic Lupus Erythematosus by Transplantation of Umbilical Cord Derived Mesenchymal Stem CellsSystemic Lupus ErythematosusBiological: mesenchymal stem cellsHebei Medical UniversityNULLNot yet recruiting14 Years60 YearsAll10Early Phase 1China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03171194
(ClinicalTrials.gov)
April 27, 20174/5/2017Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus ErythematosusA Phase I Safety Trial of Allogeneic Mesenchymal Stem Cells for Systemic Lupus ErythematosusSystem; Lupus ErythematosusDrug: Low Dose Mesenchymal Stem Cells (MSCs)Medical University of South CarolinaNULLCompleted18 Years65 YearsAll6Phase 1United States
7NCT01741857
(ClinicalTrials.gov)
January 201226/11/2012Umbilical Cord Derived Mesenchymal Stem Cells Transplantation for Active and Refractory Systemic Lupus ErythematosusPhase I/II: Umbilical Cord Derived Mesenchymal Stem Cells Transplantation For Active And Refractory Systemic Lupus ErythematosusSystemic Lupus ErythematosusBiological: human umbilical cord derived MSC transplantation for SLEThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNULLRecruiting15 Years60 YearsBoth40Phase 1/Phase 2China
8NCT00698191
(ClinicalTrials.gov)
March 200713/6/2008Mesenchymal Stem Cells Transplantation for Refractory Systemic Lupus Erythematosus (SLE)Phase I/IIa: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells Transplantation For Refractory Systemic Lupus ErythematosusRefractory Systemic Lupus ErythematosusBiological: Allogeneic MSC (AlloMSC)Nanjing Medical UniversityNational Natural Science Foundation of ChinaRecruiting15 Years70 YearsBoth20Phase 1/Phase 2China